Patents Assigned to Genentech
  • Compositions and methods for treatment of non-Hodgkin's lymphoma
    Patent number: 7410772
    Abstract: The present invention is directed to compositions of matter useful for the treatment of non-Hodgkin's lymphoma in mammals and to methods of using those compositions for the same.
    Type: Grant
    Filed: June 30, 2005
    Date of Patent: August 12, 2008
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Dylan L. Daniel, Theresa Shek
  • 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
    Patent number: 7410988
    Abstract: 2-Amido-4-substituted-aryl-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, methods of using compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions comprising compounds exhibiting ATP-utilizing enzyme inhibitory activity, are disclosed.
    Type: Grant
    Filed: August 11, 2005
    Date of Patent: August 12, 2008
    Assignee: Genentech, Inc.
    Inventors: John K. Dickson, Jr., Carl Nicholas Hodge, Jose Serafin Mendoza, Ke Chen
  • PRO6097 antibodies
    Patent number: 7411047
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: August 12, 2008
    Assignee: Genentech, Inc.
    Inventors: Kevin P. Baker, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
  • Polypeptides encoded by a nucleic acid underexpressed in melanoma
    Patent number: 7411037
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 7, 2002
    Date of Patent: August 12, 2008
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, William I. Wood
  • PRO6182 polypeptides
    Patent number: 7411040
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: August 12, 2008
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
  • Antibodies and methods for making and using them
    Publication number: 20080187966
    Abstract: The present invention provides methods for producing humanized antibodies and increasing the yield of antibodies and/or antigen binding fragments when produced in cell culture. In one aspect of the invention, at least one framework region amino acid residue of the variable domain is substituted by a corresponding amino acid from a variable domain consensus sequence subgroup that has the most sequence identity with the HVR1 and/or HVR2 amino acid sequence of the variable domain. In another aspect, an amino acid is placed at a position proximal to a cys residue that participates in an intrachain variable domain disulfide bond that corresponds to an amino acid found at that position in a variable domain consensus sequence subgroup that has the most sequence identity with the HVR1 and/or HVR2 amino acid sequence of the variable domain.
    Type: Application
    Filed: October 30, 2007
    Publication date: August 7, 2008
    Applicant: Genentech, Inc.
    Inventor: Laura Simmons
  • TREATMENT WITH ANTI-ERBB2 ANTIBODIES
    Publication number: 20080187533
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient.
    Type: Application
    Filed: January 4, 2008
    Publication date: August 7, 2008
    Applicant: Genentech, Inc.
    Inventor: Susan D. Hellmann
  • ANTI-VEGF ANTIBODIES
    Publication number: 20080187534
    Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
    Type: Application
    Filed: January 28, 2008
    Publication date: August 7, 2008
    Applicant: Genentech, Inc.
    Inventors: Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-Yee Chen
  • PRO20025 polypeptides
    Patent number: 7408034
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: August 5, 2008
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
  • PRO1188 polypeptides
    Patent number: 7408032
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: April 16, 2002
    Date of Patent: August 5, 2008
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
  • PRO5995 polypeptides
    Patent number: 7408033
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: August 5, 2008
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Anti-PRO6181 antibodies
    Patent number: 7408042
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: August 5, 2008
    Assignee: Genentech, Inc.
    Inventors: Kevin P. Baker, Maureen Beresini, Laura DeForge, Luc Desnoyers, Ellen Filvaroff, Wei-Qiang Gao, Mary E. Gerritsen, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Steven Sherwood, Victoria Smith, Timothy A. Stewart, Daniel Tumas, Colin K. Watanabe, William I. Wood, Zemin Zhang
  • Methods and compositions for selective modulation of vascularization
    Patent number: 7407660
    Abstract: The invention provides methods and compositions for modulating vascularization and angiogenesis, including selective modulation of stages of multi-step vascularization and angiogenesis.
    Type: Grant
    Filed: April 14, 2004
    Date of Patent: August 5, 2008
    Assignee: Genentech, Inc.
    Inventors: Mary E. Gerritsen, Jo-Anne S. Hongo, Constance H. Zlot
  • PRO9864 polypeptides
    Patent number: 7408035
    Abstract: The present invention is directed to novel PRO9864 polypeptides and chimeric polypeptide molecules comprising PRO9864 polypeptides fused to heterologous polypeptide sequences.
    Type: Grant
    Filed: August 13, 2002
    Date of Patent: August 5, 2008
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
  • Human DNase I hyperactive variants
    Patent number: 7407785
    Abstract: The present invention relates to amino acid sequence variants of human DNase I that have increased DNA-hydrolytic activity. The invention provides nucleic acid sequences encoding such hyperactive variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of hyperactive-variants of human DNase I.
    Type: Grant
    Filed: May 3, 2004
    Date of Patent: August 5, 2008
    Assignee: Genentech, Inc.
    Inventors: Robert A. Lazarus, Clark Qun Pan
  • Vascular Endothelial Cell Growth Factor Antagonists
    Publication number: 20080181900
    Abstract: The present invention provides human vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that are useful for the treatment of age-related macular degeneration, and other diseases and disorders characterized by undesirable or excessive neovascularization.
    Type: Application
    Filed: March 20, 2008
    Publication date: July 31, 2008
    Applicant: Genentech, Inc.
    Inventors: Napoleone Ferrara, Kyung Jin KIM
  • Polypeptides That Bind Baff And/Or April
    Publication number: 20080181886
    Abstract: The present invention relates to novel polypeptides and TACI variants that bind APRIL, novel polypeptides and TACI variants that bind BAFF, nucleic acid molecules encoding the polypeptides, host cells comprising the nucleic acid molecules, compositions comprising the polypeptides or nucleic acid molecules, and methods of using the polypeptides and nucleic acid molecules.
    Type: Application
    Filed: October 28, 2005
    Publication date: July 31, 2008
    Applicant: Genentech, Inc.
    Inventor: Robert F. Kelley
  • Assays and methods using biomarkers
    Publication number: 20080182277
    Abstract: Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of GalNac-T related molecules, such as GalNac-T14 or GalNac-T3, is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR5 agonist antibodies. Kits and articles of manufacture are also provided.
    Type: Application
    Filed: October 3, 2006
    Publication date: July 31, 2008
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Klaus W. Wagner
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Patent number: 7405269
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: July 29, 2008
    Assignee: Genentech, Inc.
    Inventors: Kevin Baker, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, William Wood
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Patent number: 7405268
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: July 29, 2008
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, William I. Wood, Colin K. Watanabe